# China NMPA Drug Inspection - Shijiazhuang Yinhu Pharmaceutical Co., Ltd. - Shuxuening Injection

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/shijiazhuang-yinhu-pharmaceutical-co-ltd/58419ef7-d067-438f-9989-7979818d6259/
Source feed: China

> China NMPA drug inspection for Shijiazhuang Yinhu Pharmaceutical Co., Ltd. published December 31, 2021. Drug: Shuxuening Injection. On December 31, 2021, the Yunnan Provincial Drug Administration published its fourth drug quality bulletin of the year, 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: The Yunnan Provincial Drug Administration issued the fourth issue of its 2021 Drug Quality Bulletin.
- Company Name: Shijiazhuang Yinhu Pharmaceutical Co., Ltd.
- Publication Date: 2021-12-31
- Drug Name: Shuxuening Injection
- Inspection Finding: [Inspection] Pyrogen levels do not meet regulations.
- Action Taken: The regulatory authorities in the production company's location inspected the company's production process and factory inspection, and found that they met the requirements and no violations of GMP and process regulations were found.
- Summary: On December 31, 2021, the Yunnan Provincial Drug Administration published its fourth drug quality bulletin of the year, detailing the results of supervision and sampling inspections conducted across the province's production, distribution, and medical facilities. This initiative was part of the 2021 Yunnan Provincial Drug Supervision and Sampling Plan, aimed at ensuring public safety and medication quality. The bulletin identified several companies for failing to meet regulatory standards. Specifically, Shijiazhuang Yinhu Pharmaceutical Co., Ltd.’s Shuxuening Injection failed testing for pyrogens. Yunnan Tengyao Pharmaceutical Co., Ltd. had two non-compliant products: Huoxiang Zhengqi Water, which exceeded microbial limits, and Yinqiao Jiedu Tablets, which failed weight variation requirements. Additionally, a medicinal wine produced by Wenshan Zhengbao Bone Injury Hospital was found to have incorrect medicinal content. These assessments were based on the Chinese Pharmacopoeia 2015 Edition and specific national drug standards. While some subsequent facility inspections reported no immediate breaches of Good Manufacturing Practices, the identified batches were officially flagged as substandard. The administration uses these findings to enforce compliance and protect consumers from ineffective or unsafe pharmaceutical products. Required actions involve the continued monitoring of these entities and the removal of substandard batches from the supply chain to maintain high standards of public health.

Company: https://www.globalkeysolutions.net/companies/shijiazhuang-yinhu-pharmaceutical-co-ltd/5e04108e-716b-451a-b0f6-f8392932ca98/